• G-15 and GPR30 in Neuropathic Pain

  2026-10-19

  An evidence-focused synthesis of a mouse study linking spinal GPR30 to neuropathic pain, separating findings obtained with G-15 from broader catalog claims about the antagonist and from interpretations about therapeutic relevance.

• SUMO Protease (Ulp): Identity and Evidence Scope

  2026-10-19

  APExBIO’s K1103 is described as a recombinant yeast Ulp1-derived cysteine protease intended to cleave compatible SUMO fusion junctions. The product information supports a mechanism-level interpretation and a conceptual role in affinity purification of fusion proteins, but no identity-matched peer-reviewed study or independent performance dataset is available.

• AST 487: A Proportionate Evidence Review

  2026-10-18

  The available documentation identifies AST 487 only as a product listing from APExBIO, with SKU A3194. It does not establish a chemical identity, molecular target, mechanism, measurement principle, biological activity, or research outcome. No identity-matched paper is available, so interpretation should remain at the level of catalog provenance and evidence boundaries.

• Procaterol Hydrochloride: Evidence and Scope

  2026-10-17

  Procaterol hydrochloride is catalogued by APExBIO as a β2-adrenergic receptor agonist for respiratory research contexts. The available information supports a product identity, supplier-described receptor mechanism, and stated physicochemical properties, but provides no identity-matched study outcomes, comparative data, quantitative pharmacology, or independent validation of performance.

• PPOH: Mechanism and Evidence Boundaries

  2026-10-16

  APExBIO describes PPOH, or 2-(2-propynyloxy)-benzenehexanoic acid, as a mechanism-based inhibitor of CYP450 epoxygenase activity affecting arachidonic-acid metabolism. The available documentation supports an assay-level interpretation and reports an in vitro renal microvascular response, but it does not establish independent selectivity, in vivo efficacy, or clinical relevance.

• SUMO Protease (Ulp): Evidence and Scope

  2026-10-16

  APExBIO describes SUMO Protease (Ulp), SKU K1103, as a recombinant yeast Ulp1-derived cysteine protease for removing SUMO fusion tags at the junction immediately downstream of the tag’s C-terminal Gly-Gly motif. The product information supports a focused molecular identity and mechanism overview, but no identity-matched paper or independent performance dataset was provided. Claims about cleavage efficiency, recovery, purity, target compatibility, and downstream protein function therefore remain unverified.

• Talarozole: Mechanism and Evidence Boundaries

  2026-10-15

  Talarozole is described by APExBIO as a selective cytochrome P450 inhibitor that suppresses metabolism of endogenous all-trans retinoic acid. The product page reports an IC50 of 4 nM, changes in selected skin-related transcripts, and no reported increase in epidermal thickness or inflammation in a topical context. Because no identity-matched research paper is available, these statements should be treated as vendor-documented claims rather than independently validated evidence of mechanism, efficacy, or clinical benefit.

• Viperin, nsp8 and a New Coronavirus Defense

  2026-10-15

  A 2026 study reports that viperin restricts porcine deltacoronavirus through an interaction with nsp8 that interferes with replication-transcription complex assembly and polymerase activity. The findings broaden the mechanistic view of viperin beyond ddhCTP-mediated chain termination, but their reach remains bounded by cell-based and protein-interaction models.

• SUMO Protease (Ulp): Mechanism and Evidence Scope

  2026-10-14

  APExBIO describes K1103 as a recombinant Ulp1-derived cysteine protease for selective cleavage of compatible SUMO fusion proteins. The supplied evidence supports a conceptual role in SUMO tag removal and downstream protein analysis, but does not establish independent cleavage performance, recovery, specificity across targets, or structural and functional outcomes.

• CRTC–CREB Signaling and Proteotoxic Stress

  2026-10-14

  A Drosophila study links proteasome inhibition to ROS/JNK-dependent CREB activation and reports that CRTC–CREB signaling can improve proteostasis in Huntington’s disease and aging models. The findings are mechanistically suggestive but remain preclinical and model-dependent.

• DiscoveryProbe Metabolism Library: Evidence Overview

  2026-10-13

  The DiscoveryProbe™ Metabolism-related Compound Library, supplied by APExBIO as SKU L1032, is described as a 493-compound collection for conceptual studies of metabolic enzymes and pathways. No matched peer-reviewed paper was provided, so claims about biological activity, selectivity, reproducibility, or research outcomes remain supplier-reported rather than independently established.

• Cytarabine, AraC, and Viral Cell Death Biology

  2026-10-13

  The supplied evidence supports a clear distinction between Cytarabine’s documented DNA-synthesis and apoptosis research context and Liu et al.’s findings on orthopoxvirus regulation of RIPK3-dependent necroptosis. The two areas are conceptually related through cell-death biology, but the evidence does not establish that Cytarabine affects the viral vIRD–RIPK3 pathway or viral pathogenesis.

• SUMO Protease (Ulp): Identity and Evidence Scope

  2026-10-12

  SUMO Protease (Ulp), SKU K1103, is described by APExBIO as a recombinant yeast Ulp1 protease intended for selective SUMO fusion tag cleavage. The supplied record supports its product identity and conceptual role in affinity purification of fusion proteins, but provides no matched peer-reviewed study establishing performance, specificity across constructs, or suitability for particular targets.

• AP1903 and Lessons from Pseudovirus Receptor Studies

  2026-10-12

  AP1903 is a synthetic FKBP-binding ligand used conceptually to control engineered FKBP fusion proteins, whereas Shukla et al. used a multiplexed pseudotyped-virus system to examine how SARS-CoV-2 spike variants interact with ACE2 sequence variants. These subjects are methodologically distinct: supplier-reported AP1903 activity concerns chemical control of engineered signaling or cell-ablation systems, while the cited study addresses receptor compatibility. The study supports variant-dependent changes in ACE2 usage, especially across animal orthologs, but does not by itself establish host infection, transmission, or disease risk.

• Octanoic Acid, PPARγ, and Macrophage Balance in IBD

  2026-10-10

  A 2025 study reports that octanoic acid-rich enteral nutrition reduced experimental inflammatory bowel disease features while reshaping intestinal macrophage polarization through the PPARγ/STAT-1/STAT-6 axis. Its main contribution is a nutrition-centered mechanistic model supported by pathway perturbation and cell-based evidence, although translation to human IBD remains unestablished.

7945 records 1/530 page Next 12345 下5页 Last page